358 related articles for article (PubMed ID: 20926745)
21. MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
Zeng B; Shi W; Tan G
BMC Cancer; 2018 Jan; 18(1):34. PubMed ID: 29304764
[TBL] [Abstract][Full Text] [Related]
22. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
23. A novel PAK4-CEBPB-CLDN4 axis involving in breast cancer cell migration and invasion.
Wang F; Gao Y; Tang L; Ning K; Geng N; Zhang H; Li Y; Li Y; Liu F; Li F
Biochem Biophys Res Commun; 2019 Apr; 511(2):404-408. PubMed ID: 30808546
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract][Full Text] [Related]
25. Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Liu H; Shi H; Fan Q; Sun X
Tumour Biol; 2016 Aug; 37(8):10161-75. PubMed ID: 26831658
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
27. Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.
Kang HW; Piao XM; Lee HY; Kim K; Seo SP; Ha YS; Kim YU; Kim WT; Kim YJ; Lee SC; Kim WJ; Shin EY; Kim EG; Yun SJ
Investig Clin Urol; 2021 Jul; 62(4):399-407. PubMed ID: 34085786
[TBL] [Abstract][Full Text] [Related]
28. NFATc1 regulates cell proliferation, migration, and invasion of ovarian cancer SKOV3 cells in vitro and in vivo.
Li L; Duan Z; Yu J; Dang HX
Oncol Rep; 2016 Aug; 36(2):918-28. PubMed ID: 27350254
[TBL] [Abstract][Full Text] [Related]
29. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
Liu F; Zhang G; Lv S; Wen X; Liu P
J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
[TBL] [Abstract][Full Text] [Related]
30. Tumorigenic role of Pak4 in ovarian cancer and its correlation with immune infiltration.
Tang L; Ye H; Chen L; Dong W; Hu X; Yu L
BMC Med Genomics; 2024 May; 17(1):148. PubMed ID: 38807162
[TBL] [Abstract][Full Text] [Related]
31. (-)-β-hydrastine suppresses the proliferation and invasion of human lung adenocarcinoma cells by inhibiting PAK4 kinase activity.
Guo B; Li X; Song S; Chen M; Cheng M; Zhao D; Li F
Oncol Rep; 2016 Apr; 35(4):2246-56. PubMed ID: 26821251
[TBL] [Abstract][Full Text] [Related]
32. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
33. LINC00339 promotes cell proliferation, migration, and invasion of ovarian cancer cells via miR-148a-3p/ROCK1 axes.
Pan L; Meng Q; Li H; Liang K; Li B
Biomed Pharmacother; 2019 Dec; 120():109423. PubMed ID: 31550677
[TBL] [Abstract][Full Text] [Related]
34. p21-Activated kinase 4 promotes prostate cancer progression through CREB.
Park MH; Lee HS; Lee CS; You ST; Kim DJ; Park BH; Kang MJ; Heo WD; Shin EY; Schwartz MA; Kim EG
Oncogene; 2013 May; 32(19):2475-82. PubMed ID: 22710715
[TBL] [Abstract][Full Text] [Related]
35. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
[TBL] [Abstract][Full Text] [Related]
36. P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation.
Xie X; Shi X; Guan H; Guo Q; Fan C; Dong W; Wang G; Li F; Shan Z; Cao L; Teng W
Oncotarget; 2017 Apr; 8(15):24882-24891. PubMed ID: 28178642
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis.
Mak GW; Chan MM; Leong VY; Lee JM; Yau TO; Ng IO; Ching YP
Cancer Res; 2011 Apr; 71(8):2949-58. PubMed ID: 21385901
[TBL] [Abstract][Full Text] [Related]
38. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer.
Erdogan MA; Ashour A; Yuca E; Gorgulu K; Ozpolat B
Cell Signal; 2021 May; 81():109938. PubMed ID: 33539938
[TBL] [Abstract][Full Text] [Related]
39. Long Noncoding RNA MIR4697HG Promotes Cell Growth and Metastasis in Human Ovarian Cancer.
Zhang LQ; Yang SQ; Wang Y; Fang Q; Chen XJ; Lu HS; Zhao LP
Anal Cell Pathol (Amst); 2017; 2017():8267863. PubMed ID: 28168162
[TBL] [Abstract][Full Text] [Related]
40. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
